Medical/Pharmaceuticals

Elekta Nomination Committee's proposed Board of Directors for the 2021 Annual General Meeting

STOCKHOLM, June 4, 2021 /PRNewswire/ -- The Nomination Committee of Elekta (EKTA-B.ST) proposes that the 2021 Annual General Meeting re-elect Board members Laurent Leksell, who is also proposed to be re-elected as Chairman of the Board, Caroline Leksell Cooke, Johan Malmquist, Wolfgang Reim, Jan Se...

2021-06-04 13:56 2658

Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

SHANGHAI and HONG KONG, June 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...

2021-06-04 08:00 4034

Vela Diagnostics Announces Collaboration with the National Cancer Centre of Singapore to Refine Novel Cancer Therapy

SINGAPORE, June 4, 2021 /PRNewswire/ -- Vela Diagnostics announced a collaboration with the National Cancer Centre ofSingapore (NCCS) to develop a molecular diagnostic assay to predict individual patients' responses to a cancer therapy called Epidermal Growth Factor Receptor (EGFR) tyrosine kinas...

2021-06-04 08:00 2614

WCPGHAN 2021: Fish oil taken during pregnancy boosts problem-solving and concentration in children, new data reveals

GENEVA, June 4, 2021 /PRNewswire/ -- Children born to mothers who took fish oil in their pregnancies have been shown to have faster problem-solving skills and better attention focus at age 10, according to findings from an EU funded study presented today at the 6th World Congress of Paediatric Ga...

2021-06-04 07:01 3218

AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021

* Lunit to present four abstracts including one in a 'Poster Discussion Session' * AI-based tissue analysis platform 'Lunit SCOPE' to be launched within the second half of 2021: "We aim to make our AI the new standard for cancer treatment" SEOUL, Korea, June 3, 2021 /PRNewswire/ -- A new find...

2021-06-04 02:14 3354

The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial

1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection (TransCon™ parathy...

2021-06-04 02:00 2939

China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection

SHANGHAI, June 3, 2021 /PRNewswire/ -- MicuRx Pharmaceutical Co., Ltd. (MicuRx), a leading biopharmaceutical company focused on the discovery, development and commercialization of antibacterial agents against drug-resistant bacterial infection, announced that China National Medical Products Admi...

2021-06-03 22:15 2182

Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, June 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...

2021-06-03 17:09 5665

Peking University Biologics entering into Strategic Cooperation Agreement with Norwich Investment Limited

HONG KONG, June 3, 2021 /PRNewswire/ -- Peking University Biologics (hereinafter known as "PKU BIO") and Norwich Investment Limited (hereinafter known as "Norwich") announced today that both parties have entered into a Strategic Cooperation Agreement ("Agreement") to promote the business develop...

2021-06-03 16:29 3863

Grifols to provide Korean Red Cross with Procleix Panther for blood screening, extending donor testing leadership in Asia

- The 28 systems to be deployed across KRC's three laboratory sites will test about 94% of the country's blood donations - They will run the Procleix Ultrio Elite Assay, an advanced nucleic acid test (NAT) ensuring donation safety by detecting the potential presence of the most important infecti...

2021-06-03 11:00 4785

Registration Open for the 4th China Medical Devices Design & Entrepreneurship Competition 2021

SUZHOU, China, June 2, 2021 /PRNewswire/ -- In order to boost the continuous innovation and development ofChina's medical device industry, deepen the cooperation among the medical device industry, universities, research institutions, users, capital sector and regulators in all aspects, and stimu...

2021-06-03 09:58 1825

Clinical Trial Results of the BCMA CAR-T Co-developed by Innovent and IASO Biotherapeutics Commented in American Society of Hematology's Medical Journal "Blood"

SAN FRANCISCO, U.S. and SUZHOU, China, June 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major ...

2021-06-03 08:00 6186

Cell Care Joins the Generate Life Sciences Family to Create a Global Platform

The acquisition provides the companies with shared scientific knowledge and resources leading to a stronger foundation for advancing newborn stem cell banking and research MELBOURNE, Australia, June 3, 2021 /PRNewswire/ -- Cell Care, Australia's leading cord blood bank, today announced it has be...

2021-06-03 06:00 3032

First Patient Dosed in QBiotics & MSD Clinical Trial Collaboration for Unresectable Melanoma

* First patient dosed with QBiotics' lead oncology molecule tigilanol tiglate in combination with KEYTRUDA® (pembrolizumab) in a clinical trial collaboration with MSD (tradename of Merck & Co., Inc.,Kenilworth, NJ, USA) * The Phase Ib/IIa study will test the safety, optimal dose and tumour re...

2021-06-03 06:00 3210

Nanoform raises its mid-term business targets for 2025

HELSINKI, June 2, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, today announced its raised mid-term business targets for 2025. The new targets are as follows:            * To nanoform annually at least 70 new active pharmaceutical ...

2021-06-02 21:42 1797

GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement

NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that they have entered into a strategic licensing agreement for Ligand's OmniAb®...

2021-06-02 21:00 9839

Shanghai Asclepius Meditec and International Department of Central Committee of CPC Collaborate to Provide Emergency Support to Fight COVID-19 in Nepal

SHANGHAI, June 2, 2021 /PRNewswire/ -- The President of Asclepius Meditec – the company behind the innovativeHydrogen Oxygen Generator with Nebulizer

2021-06-02 20:00 2257

PharmAbcine to Present at the BIO Digital International Convention 2021

DAEJEON, South Korea, June 2, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will participate in BIO Digital International Convention. The company will participate in...

2021-06-02 20:00 2945

Mindray Launches Resona I9 Ultrasound System, Revolutionizing General Imaging

SHENZHEN, China, June 2, 2021 /PRNewswire/ -- Mindray (SZSE: 300760), a global leading developer and provider of medical devices and solutions, has announced the release of its latest general imaging diagnostic ultrasound system,Resona I9 , to it...

2021-06-02 19:04 8612

Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate

INCHEON, South Korea, June 2, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment...

2021-06-02 19:00 2261
1 ... 641642643644645646647 ... 650